DaVita Inc. (DVA) Earnings Call Transcript & Summary
February 22, 2023
Earnings Call Speaker Segments
Nic Eliason
executiveThanks. Thanks for joining us for the call about our fourth quarter. We're grateful that you keep following what's happening with our company. This is Nic Eliason speaking — I serve as Group Vice President of Investor Relations — and with me on the line are our CEO, Javier Rodriguez, and our CFO, Joel Ackerman. One thing to keep in mind: comments made on this call might include forward-looking statements as defined under the federal securities laws. Known and unknown risks and uncertainties apply to each of those statements, and those factors could make what actually happens differ materially from what the forward-looking statements describe. If you want more detail on those risks and uncertainties, take a look at the press release about our fourth quarter earnings and the filings we've made with the SEC, which include our latest annual report on Form 10-K, every quarterly report on Form 10-Q filed after that, and any other documents we later file with the SEC. The information we have right now is what our forward-looking statements rest on, and we have no intention — and take on no obligation — to revise those statements unless the law says we must. Also, a reminder: certain non-GAAP financial measures will come up on this call. You can find a reconciliation between those non-GAAP measures and the closest comparable GAAP financial measures in the earnings press release we furnished to the SEC, which is also posted on our website. At this point, I'll hand things over to Javier Rodriguez.
Javier Rodriguez
executiveThank you, Nic, and I appreciate everyone being on today's call. As we enter 2023, we feel both hopeful and unsure regarding what lies ahead, while still firmly believing in our strategy and what we can accomplish over the long run. We feel fortunate to have made it through the winter with no spike in deaths tied to COVID, and, in common with a large part of society, we find ourselves asking if the darkest days of the pandemic are at last in the past. The strides we've taken lately to fix what sits inside our control give me reason for encouragement, even as we keep putting money into our future; even so, our hopefulness comes with caution right now, since volume and labor pressures are still being felt; for the moment, I'll use a few minutes to cover fourth quarter results, then turn to what's ahead by summarizing our 2023 strategic priorities, and finish with our 2023 outlook. Prior to exploring those subjects, I'll begin, in keeping with my usual practice, with a clinical highlight. The clinical efforts that carry the most weight are the ones that make a direct difference to how well our patients live and how vital they feel. Numerous metrics exist that serve this vital aim. Right now I want to pause and acknowledge the work that succeeded in bringing down infection rates among the vulnerable people we treat. One metric we use to gauge success involves monitoring bloodstream infections. It's a point of pride to report that, as of the third quarter of last year, we reached the lowest bloodstream infection rate ever recorded for our patients. That translates to a 20% gain over just the past year. What these figures show is merely one among the numerous undertakings we've pursued to lower hospitalizations and deaths, an enormous blessing for those we treat and the people who love them. I'll shift now to our results. Our adjusted operating income for the whole of 2022 landed at the upper bound of our updated guidance, reaching $1.45 billion. Adjusted earnings per share from continuing operations across full year 2022 totaled $6.60, while free cash flow came to $817 million. The main reason our fourth quarter performance hit the high end of our range was an easing in labor costs. The labor picture remains difficult along numerous fronts, yet the fourth quarter was clearly an improvement over the third. One standout: our push to cut back on contract labor yielded results sooner than we'd anticipated. We still anticipate contract labor in 2023 will exceed pre-COVID levels by $20 million-$40 million, though that represents a meaningful step up from 2022. We kept making headway bringing teammates on board during the quarter as we strive to steady staffing at our centers and boost retention. Notably, this added labor capacity will keep pushing training and onboarding expenses above what's typical throughout 2023, until retention settles back to historically normal levels; we still look for wage pressure exceeding historical norms in 2023, though we expect wage growth to come in below what we saw in 2022. Even with early hopes for gains in 2023, labor markets stay extremely volatile and will continue to be a major swing factor affecting how we perform. The results we posted for the fourth quarter leave us more confident that we can deliver the enhancements we described three months ago. Turning to volume: for Q4, the overall outcome matched the guidance we gave last quarter. Rates of COVID infection and mortality during December and January came in below those of earlier years, and that is good news for the people we treat and the staff who care for them. Since the winter surge has typically arrived late in December, the absence of one meant our treatment volumes in Q4 did not improve materially versus what we had anticipated, yet it has lowered our projection for total excess mortality in 2023 by roughly 1,000 patients compared with the range we offered last quarter. We also pointed out last quarter that patient admissions along with missed treatment rates represent a critical variable affecting our volume. Pressure on those two metrics persists, though the levels match our latest expectations. Given how unpredictable the virus remains, we are still relying on a broad span of potential volume outcomes for our 2023 guidance; we have moved that span upward to reflect the meaningful winter surge that has not materialized so far, while not entirely ruling out a Covid surge occurring later this year. Our 2023 volume guidance incorporates a treatment range spanning a decline of 3% to flat versus 2022. Holding everything else constant, if no Covid event occurs during the rest of the year, we would land nearer the stronger end of our volume range. As we look ahead to 2023, we began the year with an energetic and robust set of priorities; our dedication to pursuing strategic goals that build a strong future for the people we treat and for our company remains firm. Five of those priorities I want to emphasize today, starting with innovation. First, a major milestone in our digital modernization effort is coming up. Following years of work, during this year we are rolling out the next generation of our clinical IT platform. Built in the cloud, this new system aims to deliver seamless access to patient records across locations, supporting integrated kidney care and strengthening data reporting and analytics. Rollout is progressing nicely, and we anticipate the system being live in our centers nationwide during 2023. This platform will give our teammates and physician partners a superior experience while improving clinical care for the people we treat. Second, regarding policy, the kidney care community stays engaged, collaborating with CMMI to strengthen innovative models that improve care coordination and push forward initiatives covering transplant, home, and health equity. Simultaneously, we are advocating for an update to the industry bundle payment system so it better captures year-over-year cost increases. Lastly, we keep working alongside the broader kidney community to reinstate benefit protections for the people we treat via legislative and regulatory channels. Third, on operations, we stay dedicated to educating the people we treat and our physicians so that adoption of home modalities grows wherever it is clinically appropriate. To back our more than 1,700 current home programs, we're rolling out transitional care initiatives nationwide so that new dialysis patients can learn about their modality choices; in addition, we're moving toward fully integrating our technology platform, which would build a comprehensive information ecosystem that supports improved management of home patients. Fourth, another year of substantial patient growth is anticipated from our integrated kidney care business. Given the advantage of greater scale, this will be a pivotal year for us to keep expanding our IKC capabilities so it can fulfill its mission of producing stronger outcomes for the people we treat, improved cooperation with doctors, and financial alignment alongside our payer partners, especially in the expanding Medicare Advantage category. Last, to power these efforts, we're keeping a disciplined stance on our cost structure. That covers, for instance, our continuing shift in ESA therapy and the continuing consolidation of our facility footprint so capacity matches treatment volume. Such discipline matters especially given Medicare fee-for-service rates, which, as you're aware, haven't matched the rising costs we face in caring for patients. As is evident, 2023 is going to be a dynamic year across a number of these efforts, and we stay sharply focused on the core operating drivers I noted earlier. Now moving to outlook. For 2023, we're starting guidance for adjusted operating income of $1.4 billion-$1.6 billion and adjusted earnings per share of $5.45-$6.95. That mirrors our newest thinking on carrying on with moderating labor headwinds through the rest of the year, continued volume pressures offset by the favorable effect of dodging a winter surge, and the upside from the cost-saving initiatives we've already described. Over a longer horizon, should we keep witnessing reduced COVID impacts and easing labor pressure, we'd anticipate going back to a more typical adjusted OI growth trajectory of 3%-7%. I'll now hand things to Joel so he can cover our financial performance and outlook in greater detail.
Joel Ackerman
executiveAppreciate that, Javier. First off, I'll give a bit more depth on how Q4 came out, and after that I'll provide some additional context around the 2023 guidance. On Q4, adjusted operating income came to $317 million, and adjusted earnings per share from continuing operations was $1.11, which put the full year right at the top end of the updated guidance range we gave you last quarter. Within the US dialysis segment, treatments per day declined 1.3% versus the third quarter, which matched what we had expected. That came from a lower patient count driven by excess mortality along with a higher seasonal mistreatment rate. Sequentially, adjusted patient care cost per treatment rose $1.78. Three main factors drove that increase: seasonal flu expense, year-end benefits, and reduced fixed cost leverage stemming from the drop in treatment volume. Lower contract labor costs during the quarter partly offset those. Adjusted G&A fell $24 million from the prior quarter. That decline was mostly attributable to the $28 million of California ballot initiative expense recorded in Q3. Moving to our other segments: in our IKC business, operating income was about flat versus the prior quarter. International adjusted operating income dropped $15 million quarter-over-quarter. That was mainly the result of $7 million in foreign exchange headwinds plus an expense tied to acquisitions in Brazil. That acquisition expense is offset by a decrease in taxes, so the P&L sees no net impact. We didn't buy back any shares during Q4. As we said on the Q3 call, paying down debt is our main use of excess capital so we can get back to our target leverage ratio of 3 to 3.5 times EBITDA. Now to 2023 — I'll give you some additional detail on our guidance. Our adjusted operating income guidance for 2023 sits at $1.4 billion-$1.6 billion. Relative to what we said on the Q3 call regarding our 2023 expectations, the sole meaningful change is higher treatment volume because there was no winter COVID surge. To add more color, I'll walk through our latest expectations for the three drivers of the U.S. dialysis business in 2023. First, we project the year-over-year change in treatment volume to land between 0% and negative 3%, largely because excess mortality in 2022 annualizes and excess mortality continues through 2023. Second, we anticipate revenue per treatment to rise roughly 2% to 2.5% year-over-year, with about 2/3 coming from rate increases and 1/3 from higher Medicare Advantage and commercial mix. Third, we expect patient care cost per treatment to go up approximately 2% to 2.5%, driven by wage rate growth and inflationary pressures, partly offset by savings from our new anemia contract and other cost-saving initiatives. A few more items to help frame your thinking on 2023, all of which are baked into our guidance. Year-over-year adjusted operating income gets a benefit of approximately $50 million because the ballot initiative spend is absent in 2023. On the timing of adjusted operating income for 2023: because of normal seasonality affecting items such as RPT, treatment days each quarter, and labor, among other things, we expect Q1 adjusted OI to come in roughly $75 million to $100 million below the Q2 through Q4 average. As for the Medtronic agreement we disclosed earlier, we expect it to close during the first half of this year. At closing, our initial cash investment will be about $300 million. On the P&L, we're anticipating roughly $60 million of pre-tax losses below OI in 2023, assuming about $30 million in Q2 and $15 million each quarter for the rest of the year. The resulting EPS impact in 2023 will be about $0.47. At IKC, we expect OI in 2023 to be flat to slightly down versus 2022, driven by extra growth expenses partly offset by higher shared savings. Our assumption for interest expense this year is $405 million to $425 million. On income tax, we anticipate an effective rate of 25% to 27%. Turning to cash flow, we expect free cash flow from continuing operations of $650 million to $900 million. Last, we anticipate our leverage ratio at the close of 2023 landing between 3.6x and 3.9x 2023 EBITDA. That wraps up our prepared comments for today. Operator, please open the call for Q&A.
Andrew Mok
analystHello, and good afternoon. First off, you hit the upper end of the updated outlook this quarter, and you're keeping OI growth for 2023 the same. Could you give us a clearer picture of what's driving that? It seems like both labor expenses and volumes are moving in a favorable direction, which presumably should mean a stronger OI forecast for 2023. Thank you.
Joel Ackerman
executiveAndrew, hi. I'll handle that question. Compared with the guidance we provided on the Q3 call, we've genuinely come to understand two things. First, as you pointed out, the quarter landed at the top of our range, mostly because of labor. Second, a winter surge never materialized. When we put together guidance for the year, we factored in the volume gain from the absence of a winter surge. We examined the labor situation, and in the end, we decided to keep our labor guidance for 2023 as it was, for essentially two reasons. First, we did observe improvement in Q4, but a portion of that was improvement we had actually expected during the front half of 2023. It simply arrived sooner than we thought, so you wouldn't anticipate that altering 2023. The second is that the labor environment is highly dynamic, and with so many moving pieces, we ultimately decided that a single quarter of outperformance wasn't sufficient yet for us to revise our views. Because of that, we left labor where it stands, and the upgrade in the guide for next year really stems from better volume due to no COVID surge during the winter.
Andrew Mok
analystUnderstood. Can you provide the figure for contract labor costs during the quarter?
Joel Ackerman
executiveYes. Relative to Q3, contract labor costs in Q4 declined by roughly $14 million.
Andrew Mok
analystAlright. During the prepared remarks, you mentioned that a return to a more typical OI trajectory of 3%-7% would be expected if COVID normalizes. Could you help us grasp how much visibility you actually have into incidence rates for new patients — enough to give you, you know, confidence in that restored growth rate once COVID normalizes?
Javier Rodriguez
executiveSure. I'll take that one. Basically, when we consider growth, we break it into two buckets. One bucket is what we control ourselves. The other bucket is macro factors. On the side we control, as we've mentioned, during the fourth quarter, we achieved some progress. We'll keep making progress when it comes to being staffed and ready to accept new patients. On the macro side, which is more or less the question a lot of people are raising, how does upstream new patient look? Certain questions remain that we still cannot quantify, certain variables that we still cannot quantify. Having said that, nothing we've observed causes us to reach the conclusion that a permanent shift to new starts exists. The best assumption at this point is to assume that once COVID plays out, that admits would revert to the roughly 2% that we experienced historically.
Andrew Mok
analystUnderstood. One more question, if I may. I'd like to ask regarding the ESA changeover, moving from EPOGEN to MIRCERA. What kind of pace do you anticipate when it comes to shifting patients over? What has been accomplished up to now, and at what point do you anticipate that shift will wrap up? Thank you.
Javier Rodriguez
executiveYes. That pace is clearly finished, handled very cautiously while working alongside every physician, who each make their own separate choices about what suits each individual patient; it will be implemented across the year, and by the close of 2023 we ought to have it finished.
Andrew Mok
analystGreat. Thanks for the color.
Javier Rodriguez
executiveThank you.
Pito Chickering
analystHello, everybody. Good afternoon. Let's spend a few more minutes discussing the incidents subject. I understand this is pretty late, but looking at the USRDS incident count, the first six months of 2022 are roughly 5% lower compared to 2021. Could you assist in putting numbers to what your new adds were on a quarterly basis across 2022? What are you all assuming regarding that for 2023?
Joel Ackerman
executiveThe rate at which we admitted patients during 2022 came in below the level we had experienced before COVID. We highlighted that, and I believe that is genuinely among the major factors behind why, as I'd describe it, organic volume or organic growth has declined. This has remained consistent. Things sort of accelerated during the latter six months, and that level hasn't dropped since, so our 2023 outlook essentially mirrors the pattern from 2022. No significant gains have been assumed in there. Still, per Javier's comments, we anticipate a return to pre-COVID conditions after COVID's direct and indirect effects have fully played out.
Pito Chickering
analystAlright. From what I can see in the press release, roughly 1,200 patients were added on a sequential basis. I suppose — actually, could you give us a figure — is it 6,000 additions, with the difference largely reflecting mortality? I mean, is there any detail you can offer, any way to put a number on what the new adds came to during the fourth quarter?
Joel Ackerman
executiveHistorically, we have not disclosed a figure for new adds, and I'm reluctant to provide one at this point. There are probably many ways one could go about calculating it. I'm not certain I can give you a solid answer on that figure. That being said, look, it remains at a depressed level. We observed that in Q4. Seasonality affects that figure; it typically strengthens during the first half of the year. Clearly, we will be watching for that during the first half of 2023.
Javier Rodriguez
executiveRight. Suppose someone applied more advanced mathematics here — I'm simply attempting to point us in a useful direction — and the result you arrive at is negative 3 to 0, meaning the middle value comes out to negative 1.5. Should you merely calculate from the excess mortality figure at the outset, during 2023, you land at roughly negative 2. Additional factors do play a role, yet that calculation would bring you to approximately positive 50 basis points for new admits, more or less. Other forces are also at work, but this at least offers some direction.
Pito Chickering
analystActually, this works as a transition into my next point. I mean, you know, I suppose before COVID hit, back in 2019, what you typically observed was a mortality rate around 17%, which works out to slightly less than 6 years on average. Then in 2020, it was, you know, a mortality rate above 20%, which is under 5 years. I guess, when you look at the fourth quarter here, are mortality rates trending back toward where they were before? You know, at some point there were expectations that it would be extended, simply because of a pull forward from excess mortality due to COVID, you know, in 2021. Just checking, you know, whether that figure is beginning to stretch back out again.
Javier Rodriguez
executiveYeah. If you, if you simply take a look at the figures just to be sure, because there are new people following the story, in 2020 we reported approximately 6,800 or so excess mortality, and our guidance is roughly to 3,000 in 2023; it's declining pretty sharply. I think, you know, once again, we don't have exact visibility into when that would return, but as COVID fades, it appears like it would; given the visibility we have, it should return to normal.
Joel Ackerman
executiveYes, Peter, and to give you a hand with your modeling, let me add something there. The figure for excess mortality in Q4, as we currently understand it — and keep in mind these figures do get revised as more data comes in — came to about 900. Should you wish to set that against Q4 of 2021, the figure then stood at approximately 1,500. So comparing Q4 with Q4, there's been a substantial decline.
Pito Chickering
analystAll right, that's good.
Joel Ackerman
executiveSince that spike won't be there, we'd anticipate the same pattern for Q1 2023 versus Q1 2022.
Pito Chickering
analystAll right. A brief second question. Could you discuss the turnover among nurses? Is it now more or less steady? And regarding contract labor, how much were we spending on that back in 2019, just while we consider what a return to normal looks like, where we're halting contract labor as it was before COVID?
Javier Rodriguez
executiveBefore COVID, it was about just under $20 million. At the peak, we reached about $100 million in the prior year, and our guidance was that we'd be about $20 million to $30 million above that in 2023, which lands you at approximately $50 or so. Basically aiming to be halfway there.
Pito Chickering
analystOkay, great. Thanks so much, guys.
Javier Rodriguez
executiveThank you.
Gary Taylor
analystHello, and good afternoon, everyone. I have two brief items to ask about. Turning back to Integrated Kidney Care, with those 42,000 patients under full risk, what does the outlook include for 2023? What amount of growth in patients?
Joel Ackerman
executiveFor that, Gary, I would suggest using 50% as a solid figure.
Gary Taylor
analystSo we're looking at a 50% increase in patients, and you're indicating the loss will be pretty much in line with, maybe a bit better than, that $125 — is that right?
Joel Ackerman
executiveCorrect. The way I'd frame it with approximate figures is that shared savings revenue improves by $50 million, and the main driver there is the shared savings from 2023 for patients we had at risk during 2022, and that gets offset by about $50 million in costs tied to the growth we expect in 2023.
Gary Taylor
analystThat's logical. My understanding of the accounting treatment for that is, you recorded $378 million of revenue for the segment this year, and you have roughly $3.5 billion of spend. I realize not everything is necessarily ratable, but that suggests your net savings flowing into the revenue figures is around 11% of the spend. Is that the correct way to view the results you're delivering thus far?
Joel Ackerman
executiveI'd say performing that calculation is difficult. The $377 million of revenue in 2022 arrives in two buckets, really. $300 million comes from the SNPs, which I'd term gross revenue. Consider it as accounting comparable to a health plan's approach, in which the entire medical cost flows through revenue. The remaining $76 million is shared savings revenue, and there we record only the actual shared savings amount, not the full cost of the medical amount. If you truly wanted to examine a figure, you would take what I'd call the gross margin tied to that $377 million. It isn't. That isn't a gross margin under accounting rules. This is a sort of financial calculation we would perform. It wouldn't be GAAP-compliant. You divide that figure, which is, let's say, $100 million, by the previous year's medical spend or the dollars under management from the prior year, since that shared savings revenue relates to the prior year, and that ratio would bring you to what I'd term a net savings figure.
Gary Taylor
analystUnderstood. I'm tracking with you. Thanks for that. One final item. Javier, you were discussing.
Joel Ackerman
executiveGary, apologies. A fast fix here. I believe you stated that 2023 would come in flat to slightly better than 2023, and I went along with it. What I actually said during the prepared remarks was flat to slightly worse. I simply wanted to.
Gary Taylor
analystSlightly worse.
Joel Ackerman
executiveto clean that up.
Gary Taylor
analystAll right, thank you. I'd like to turn to Marietta briefly. Javier, Fresenius has expressed a great deal of confidence regarding regulatory or legislative action, and you indicated you remain engaged on that front. So, I'm wondering whether there's anything additional you can tell us about where you believe that relief is more apt to materialize — CMS altering regulatory language, or the legislation that came out last year? And the final piece would be whether there's any indication whatsoever that any of the regional TPAs have begun doing anything with this yet? Based on your commercial mix guidance for 2023, it doesn't sound like it, but I just wanted to check.
Javier Rodriguez
executiveThanks, Gary, for that question. I won't guess at the manner in which it might arrive, or whether it will arrive, or the timing, but we keep working very hard alongside the kidney community and disability groups to bring back our safeguards for our patients. Regarding what we're observing, no meaningful uptick has appeared, though we wouldn't anticipate one at this point in the year, since claims and payments tend to lag. At present, things are unfolding as we expected. One item we're pursuing with congressional champions: they've requested that we put together examples, because protecting patients matters greatly to them; that's, that's the extent of what we have right now.
Gary Taylor
analystAlright, great — thanks.
Javier Rodriguez
executiveThank you. And I’ll also note 6,300.
Analyst
analystHey everybody, Austin here filling in for Justin. Thanks for the questions. Joel, I'd like to begin really quickly with the leverage outlook, that 3.6 to 3.9 figure you mentioned. First, I'm just sort of wondering what would have to occur to hit either end of that range. Then, regarding the share repo, is there any timing or outlook baked into the 2023 guide for when that might start up again? Or put differently, what do you folks need to see on the debt side before buyback activity begins again?
Joel Ackerman
executiveNo share repurchases have been included in our guidance for next year. We simply believe that's the wise approach for modeling things out. The range mostly comes from the range in OI, which turns into a range in EBITDA. That is what causes the range there; as for what we'd need to see, look, we'd need a very clear path to getting back into the range before our capital allocation priorities would shift back to share repurchases.
Analyst
analystAll right, sounds good. Following up a bit more on shutting down clinics — you completed 44 during the prior quarter, and 58 in this one. Thinking ahead toward 2023, is there some sort of specific figure you're aiming for when it comes to additional clinic consolidation? And along those lines, could you give a quick update on how patient retention is trending as a result?
Javier Rodriguez
executiveSure; there isn't a target as such. As you'd expect, this is something we handle with tremendous seriousness to ensure patients receive proper care and that communities receive proper care, and we look at many different factors. It appears the range will land somewhere between 50 and 70 in 2023 clinics that will probably consolidate. When it comes to keeping patients, that's a variable that feeds into, that's included within that assessment, and we keep observing robust retention of patients who wish to remain with DaVita.
Analyst
analystGreat. For my final question, it's sort of an IKC follow-up. You know, the count of at-risk patients, you know, fluctuates somewhat throughout the year. I'm just curious, you know, what's driving that when it comes to attribution to you guys? Should we expect that, like, patient mortality in some sense is kind of appearing there? On the med cost under management, I suppose, what are the expectations for cadence and how that shifts across 2023?
Joel Ackerman
executiveThere's nothing I would highlight regarding the movement on the lives over the course of the year. You know, contracts increase or decrease. You know, the number of lives in our SNF plans can shift a little bit. Some of it, I think this quarter was more about rounding than any significant moves. Regarding Medical spend under management, I think, for next year, we anticipate that figure to land somewhere in the $5 billion range with a lot of that growth arriving, at the beginning of the year.
Analyst
analystGreat. My apologies, let me jump in with just one additional question. You folks brought up the commercial mix in MA. I'm just curious roughly how that performed in 4Q, and then what sort of figure is baked in for year-end 2023, purely regarding the mix side.
Javier Rodriguez
executiveWe closed out the year at a mix of 10.4, and while we typically don't provide forward guidance on a mix, that's the level where we finished the year.
Analyst
analystGreat. Thanks, guys.
Javier Rodriguez
executiveThank you.
Kevin Fischbeck
analystThanks, that's helpful. I believe on the previous quarter's call, you had quite a bit to say about what's happening with the mistreatment trend. Any new information on that front? From what you're describing, it seems like the number landed where seasonality would suggest. So does that put it back at a typical level, or back to what you'd have anticipated given the pattern from Q3 combined with the seasonal effects in Q4?
Javier Rodriguez
executiveKevin, regarding mistreatments, what we pointed out is that the rate was running one percentage point above its historical norm; we also noted that this is something that will require time, first, to grasp, and second, to correct; when we built our guidance, we assumed no meaningful improvement on that front until we genuinely get a handle on what's driving it and bring it down. Saying it came in line means it was never projected to get better in any substantial way.
Kevin Fischbeck
analystWhen you put forward that volume outlook of 0% to -3%, is the assumption behind it simply that things remain steady?
Javier Rodriguez
executiveYes, that's right.
Kevin Fischbeck
analystAlright. Regarding that Medtronic joint venture, from what I'm hearing, it's roughly $15 million each quarter for the remainder of this year; that's our assumption... At what point do you expect it to reach break even? Does that scale in a ratable way toward whatever that year turns out to be?
Javier Rodriguez
executiveYes, I'd call ratable through 2026 a fair estimate.
Kevin Fischbeck
analystAlright. Assuming leverage stays in that 3.6 to 3.9 band, going back to what was said earlier, can we safely figure there also won't be any share repo during the first half of next year? If core growth seems to be happening, maybe that deleveraging path opens up, which would let you, you know, kick off repo before you're actually sitting right at that range.
Javier Rodriguez
executiveMy sense is it's a bit early to speculate, though we definitely want to keep the optionality to launch the share repurchase program before reaching that point. I'm not saying we're going to, but we'd want to know there's a clear path to getting there.
Kevin Fischbeck
analystOkay. Maybe we can go back to the mix question. You both stressed it — I think you said it was responsible for a third of the rate increase in 2023. Given that everyone anticipates a recession at some point, it sounds like your assumption is still that commercial goes up. Does that come down to member months and when those job cuts happen, which would make it more of a 2024 issue than a 2023 one? If you could add some detail, more detail on MA penetration right now and where you see that heading down the road. Thank you.
Joel Ackerman
executiveRegarding the private pay mix and how a recession might affect it — that really hinges on which segments take the hit and how long the downturn goes on. Our patients have shown they're eager to sign up for COBRA and hold onto their coverage. On top of that, they've done really well with coverage through the exchanges, which should make things more resilient. And naturally, if a recession keeps going, the impact is anyone's guess. If we assume this downturn lasts about as long as a typical one, then I'd say patients have shown they lean toward holding onto their private coverage. As for your other question—the one about MA mix, I believe—we closed out the year at 47.3%. We're now in a period of standard open enrollment, and what we keep observing is a bit of an uptick each quarter, so that figure will keep climbing. If you asked me to guess where it settles over the long haul, I'd say a touch under 50, or roughly 50.
Kevin Fischbeck
analystAlright, excellent. Perhaps only one final item. Regarding that cost-reduction program you carried out, I mean, maybe it's simply that we now have greater detail when it comes to the charges and all the other things you laid out here. I just want to confirm whether this is, more or less, pretty much what you had in mind during the prior quarter, or did you speed anything up, or handle anything, you know, in a different way once Q4 unfolded?
Javier Rodriguez
executiveNo, I believe Joel put it nicely, that we are carrying out exactly what we promised in Q3 across every one of the areas we mentioned. When it comes to labor, a few of those efficiencies arrived just a bit quicker than we expected. Everything else stays the same.
Kevin Fischbeck
analystAll right, great. Thanks.
Javier Rodriguez
executiveThank you.
Andrew Mok
analystGreat. Just a handful of numerical items as a follow-up. Your D&A went up roughly $20 million on a sequential basis. Does that stem from the fresh clinical IT investments, or is some other factor pushing D&A up in the quarter? Is that a reasonable figure to use for 2023 when thinking about the run rate?
Javier Rodriguez
executiveWhen it comes to modeling consolidated D&A for 2023, I would say our expectation is that it won't shift a great deal relative to the full year 2022.
Andrew Mok
analystSo what you're telling me is that on a full-year basis, D&A is going to hold steady, even though it moved higher during the fourth quarter?
Javier Rodriguez
executiveThat's right.
Andrew Mok
analystSo what's behind that drop? Does it come from fewer clinics?
Javier Rodriguez
executiveAndrew, the key point to keep in mind here would be the non-GAAP D&A. Costs tied to shuttered clinics, plus anything else of that kind, have to be taken out. Once you're on a non-GAAP basis, my sense is that Q4 looks pretty much level with Q3.
Andrew Mok
analystAll right, understood. Perhaps a brief status on the home dialysis programs. How does that compare with our longer-term objectives? Given that you're closing clinics, is it reasonable to anticipate that figure rising as time goes on? Thank you.
Javier Rodriguez
executiveYes. Appreciate that, Andrew. The proportion for home came in at 15.2%, which aligns with what we had projected. In our view, there isn't a connection between shutting down facilities and a rise in home mix. Instead, it's the transitional centers we mentioned, along with ensuring patients have remote monitoring for home and other resources, so they feel assured, connected, and eager to transition home; we are, basically, also providing further education to nephrologists so they feel at ease managing a greater number of patients at home. Those factors matter far more than the centers do, since we are being extremely careful about which clinics get closed, and patients, basically, continue to have access.
Andrew Mok
analystUnderstood. Regarding that topic, I believe you mentioned it quickly, yet what precisely are you doing so that patients remain with you at the clinics you shut down? What steps are being taken to stop any kind of loss there?
Javier Rodriguez
executiveOf course, patients get to decide, and so do their nephrologists, who may send them anywhere they consider suitable for their lives. Generally speaking, we have connections with them, and they are at ease with the treatment they receive. Whenever we meet with someone and inform them that a center is closing, we explain the choices available, after which they make their selection, and often they are at ease remaining at a DaVita center. Those who clearly opt to head elsewhere do head elsewhere, yet a large majority have chosen to remain with DaVita and their nephrologist.
Andrew Mok
analystUnderstood — appreciate all the detail.
Javier Rodriguez
executiveThanks.
Javier Rodriguez
executiveAll right, Michelle, thanks. I appreciate everyone's questions and the ongoing interest you've shown in DaVita. I'll wrap up the same way I began, feeling hopeful about what's coming in the year ahead. While we're still not going to make any forecasts regarding COVID, the strides we've made lately give me reason for encouragement. As we laid out today, we'll keep working toward our strategic priorities so that we can build the strongest long-term capabilities and results for our patients, our teammates, and our shareholders. Thanks to each of you for being on the call today, and take care.
Operator
operatorThank you; this concludes today's conference call. You may go ahead and disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.